← Back to Search

Bereavement Support Intervention for Grief Reaction

N/A

Waitlist Available

Led By Brandi Vanderspank-Wright, Phd,RN

Research Sponsored by Ottawa Hospital Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months post death

Awards & highlights

Study Summary

This trialexplores a bereavement support program for families of people who died in the ICU, to prevent severe grief reactions and improve their long-term psychological wellbeing.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months post death

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months post death

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months post death for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Bereavement Dependency Scale (BDS)

Brief Grief Questionnaire (BGQ)

Impact of Events Scale - Revised (IES-r)

+2 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Virtual meeting with the care team to address unmet needsExperimental Treatment1 Intervention

At 8-12 weeks post-death, we will contact FMs and invite them to meet virtually with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.

Group II: Offering a facilitated storytelling intervention sessionExperimental Treatment1 Intervention

At six months post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). FMs who complete all questionnaires will be invited to participate in a 1-2-hour narrative exploration of their grief and bereavement experience, regardless of the severity of their symptoms. Those with severe symptoms will be notified of symptom severity, with a suggestion to participate in the narrative exploration of their grief and bereavement experience. Storytelling interventions require specialized resources but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may only be helpful for selected FMs. Storytelling interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.

Group III: Educational material and personalized card of condolenceExperimental Treatment1 Intervention

Members of the ICU team who cared for deceased ICU patients will be asked to send a letter of condolence to family members listed as the patient's primary contact and provide them with educational modules related to bereavement support for family members.

Group IV: Educational Intervention for ICU-Based CliniciansExperimental Treatment1 Intervention

ICU-based clinicians (e.g. physicians, RNs, and social workers) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Education

2017

N/A

~4770

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor

561 Previous Clinical Trials

2,785,561 Total Patients Enrolled

Canadian Virtual HospiceUNKNOWN

1 Previous Clinical Trials

594 Total Patients Enrolled

Brandi Vanderspank-Wright, Phd,RNPrincipal InvestigatorInvestigator

Media Library

Offering a facilitated storytelling intervention session Clinical Trial Eligibility Overview. Trial Name: NCT03985592 — N/A

Grief Reaction Research Study Groups: Offering a facilitated storytelling intervention session, Educational Intervention for ICU-Based Clinicians, Educational material and personalized card of condolence, Virtual meeting with the care team to address unmet needs

Grief Reaction Clinical Trial 2023: Offering a facilitated storytelling intervention session Highlights & Side Effects. Trial Name: NCT03985592 — N/A

Offering a facilitated storytelling intervention session 2023 Treatment Timeline for Medical Study. Trial Name: NCT03985592 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for enrolment in this investigation?

"Data on clinicaltrials.gov indicates that this study is not currently accepting patients, with the trial's initial posting occurring February 2nd 2020 and its last edit taking place May 19th 2021. Despite the lack of patient recruitment for this particular intervention, there are 1 other current trials searching for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

ICU BEREAVE: Feasibility of a Multi-component Bereavement Support Intervention to Prevent Severe Grief Reaction

James Downar 2020. "ICU BEREAVE: Feasibility of a Multi-component Bereavement Support Intervention to Prevent Severe Grief Reaction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03985592.